论文部分内容阅读
目的 探讨HBV相关慢加急性肝衰竭(HBV-ACLF)患者血中IL-37水平的临床意义.方法 所有病例均为苏州大学附属第一医院感染病科2016年1月—2017年12月收治的患者,其中肝衰竭患者35 例(HBV-ACLF组),慢性乙型肝炎(CHB)患者25 例(CHB组)和同期18 名健康体检者(正常对照组).采用ELISA法检测3组人群的血清IL-37水平,同时检测总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)等临床指标.结果 HBV-ACLF组、CHB组IL-37的表达较正常对照组明显升高,差异有统计学意义(P＜0.05),HBV-ACLF组IL-37的表达较CHB组升高,差异有统计学意义(P＜0.05).结论 HBV-ACLF患者血清IL-37升高,监测其动态变化对预测患者预后具有重要意义.“,”Objective To investigate the clinical significance of serum IL-37 level in patients with HBV related chronic acute liver failure (HBV-ACLF). Methods all cases were treated in the Department of Infectious Diseases of First Hospital Affiliated to Soochow University from January 2016 to December 2017, including 35 patients with liver failure (HBV-ACLF group), 25 cases of chronic hepatitis B (CHB) in the same period (CHB group) and 18 healthy controls (NC group). ELISA method was used to detect the serum IL-37 level of 3 groups, and the clinical indicators were detected at the same time. Results IL-37 in HBV-ACLF group and CHB group was significantly higher than that in NC group, the difference was statistically significant, HBV-ACLF group was higher than CHB group, the difference was statistically significant. Conclusion The serum IL-37 level in patients with HBV-ACLF is elevated. Monitoring its dynamic changes is of great significance in predicting the prognosis of patients with HBV-ACLF.